WILEX AG

 

 

ENGLISH DEUTSCH

Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.

 

Latest News

19.06.2017: Adhoc- and press release: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates ...More

 

 

 

 

Seite gelesen: 87833 | Heute: 178